MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhep.2022.02.020

Медицинская библиотека · Journal of hepatology · 2022

Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection.

Gehring Adam J, Mendez Patricia, Richter Kirsten, Ertl Hildegund, Donaldson Eric F, Mishra Poonam, Maini Mala, Boonstra Andre, Lauer Georg, de Creus An, Whitaker Kathleen, Martinez Sara Ferrando, Weber Jessica, Gainor Emily, Miller Veronica

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

There have been unprecedented advances in the identification of new treatment targets for chronic hepatitis B that are being developed with the goal of achieving functional cure in patients who would otherwise require lifelong nucleoside analogue treatment. Many of the new investigational therapies either directly target the immune system or are anticipated to impact immunity indirectly through modulation of the viral lifecycle and antigen production. While new viral biomarkers (HBV RNA, HBcAg, small, middle, large HBs isoforms) are proceeding through validation steps in clinical studies, immunological biomarkers are non-existent outside of clinical assays for antibodies to HBs, HBc and HBe. To develop clinically applicable immunological biomarkers to measure mechanisms of action, inform logical combination strategies, and guide clinical management for use and discontinuation of immune-targeting drugs, immune assays must be incorporated into phase I/II clinical trials. This paper will discuss the importance of sample collection, the assays available for immunological analyses, their advantages/disadvantages and suggestions for their implementation in clinical trials. Careful consideration must be given to ensure appropriate immunological studies are included as a primary component of the trial with deeper immunological analysis provided by ancillary studies. Standardising immunological assays and data obtained from clinical trials will identify biomarkers that can be deployed in the clinic, independently of specialised immunology laboratories.

Для цитирования: Gehring Adam J, Mendez Patricia, Richter Kirsten, Ertl Hildegund, Donaldson Eric F, Mishra Poonam, Maini Mala, Boonstra Andre, Lauer Georg, de Creus An, Whitaker Kathleen, Martinez Sara Ferrando, Weber Jessica, Gainor Emily, Miller Veronica. Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection.. Journal of hepatology. 2022. DOI: 10.1016/j.jhep.2022.02.020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.